The estimated Net Worth of G Bradley Cole is at least 7.92 百万$ dollars as of 5 June 2024. Mr Cole owns over 4,373 units of Exact Sciences stock worth over 600,997$ and over the last 19 years he sold EXAS stock worth over 6,088,151$. In addition, he makes 1,228,010$ as Gen. Mang. of Precision Oncology at Exact Sciences.
Mr has made over 102 trades of the Exact Sciences stock since 2011, according to the Form 4 filled with the SEC. Most recently he exercised 4,373 units of EXAS stock worth 280,397$ on 5 June 2024.
The largest trade he's ever made was exercising 60,000 units of Exact Sciences stock on 12 August 2019 worth over 1,760,400$. On average, Mr trades about 4,207 units every 32 days since 2005. As of 5 June 2024 he still owns at least 9,373 units of Exact Sciences stock.
You can see the complete history of Mr Cole stock trades at the bottom of the page.
G. Bradley Cole is the Gen. Mang. of Precision Oncology at Exact Sciences.
As the Gen. Mang. of Precision Oncology of Exact Sciences, the total compensation of Mr Cole at Exact Sciences is 1,228,010$. There are 8 executives at Exact Sciences getting paid more, with Kevin Conroy having the highest compensation of 18,716,500$.
Mr Cole is 64, he's been the Gen. Mang. of Precision Oncology of Exact Sciences since . There are 7 older and 18 younger executives at Exact Sciences. The oldest executive at Exact Sciences Corp. is James Doyle, 74, who is the Independent Director.
G's mailing address filed with the SEC is C/O KINIKSA PHARMACEUTICALS, LTD., CLARENDON HOUSE 2 CHURCH STREET, HAMILTON, D0, HM 11.
Over the last 21 years, insiders at Exact Sciences have traded over 118,141,352$ worth of Exact Sciences stock and bought 191,930 units worth 1,451,887$ . The most active insiders traders include Kevin T Conroy、Edwin M Jr Kania、Maneesh Arora. On average, Exact Sciences executives and independent directors trade stock every 12 days with the average trade being worth of 1,667,056$. The most recent stock trade was executed by Brian Baranick on 5 August 2024, trading 2,712 units of EXAS stock currently worth 173,893$.
exact sciences is a molecular diagnostics company focused on colorectal cancer. the company has exclusive intellectual property protecting its non-invasive, molecular screening technology for the detection of colorectal cancer. stool-based dna (sdna) technology is included in the colorectal cancer screening guidelines of the american cancer society and the u.s. multi-society task force on colorectal cancer. for more information on exact sciences' noninvasive colon cancer screening test, visit cologuardtest.com
Exact Sciences executives and other stock owners filed with the SEC include: